This year, the Faculty of Medicine's anniversary events will take place on October 10th and 11th. We invite all interested parties to submit abstracts for the Faculty of Medicine's anniversary research conference by May 27, 2024
Surprisingly high fraction of infertile men presenting congenital testicular maldescent, were revealed as stated in a recent publication by researchers University of Tartu.
Approximately one in seven couples face difficulties conceiving a child naturally. Half of these cases are due to male infertility – either caused by the complete absence or low number of mature sperm.
Discounted group tickets for the alumni get-together are available from 18 to 30 April. Now it’s time to call your university friends: instead of the 45-euro single ticket, you can buy two 35-euro tickets or ten tickets for 30 euros each.
The general assembly of the Estonian Academy of Science selected Pärt Peterson, Professor of Molecular Immunology at the University of Tartu as a member of the academy in the field of biomedicine.
Imagining a future entirely different from today can be the most effective risk adaptation strategy. At the Scientific Advisory Board’s conference “Viirustega tulevikku” (“To the future with viruses”), a panel of top Estonian scientists and officials discussed what resources and decisions future pandemics require and what trends influence how Estonian society will cope with pandemics in the upcoming decades. The panel discussion “Pandemics in a future society” was moderated by Triin Vihalemm, Professor of Communication Studies at the University of Tartu.
The University of Tartu will organise its alumni get-together with the slogan “Back to the university” on 18 May 2024. Early-bird tickets at special rates are available from 1 December.
Last week, the US Food and Drug Administration (FDA) approved the world's first vaccine against the chikungunya virus – Ixchiq. The vaccine candidate has been designed and manufactured at the University of Tartu. The human clinical trials were conducted by the biotechnology company Valneva Austria GmbH.